Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025, and September 26, 2025, of the upcoming lead plaintiff deadline on March 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SDM securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Smart Digital made false and misleading statements and failed to disclose critical information regarding market manipulation and fraudulent promotion schemes [5]. - Specific allegations include the use of offshore accounts for share dumping, omission of risks related to fraudulent trading, and misleading positive statements about the company's business and prospects [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Beyond Meat, Inc. securities between February 27, 2025, and November 11, 2025, of the March 24, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Beyond Meat securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Beyond Meat made materially false and misleading statements regarding the fair value of its long-lived assets, which could lead to a significant non-cash impairment charge [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering substantial amounts for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable ranking by ISS Securities Class Action Services [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Snowflake Inc. Class A common stock during the specified Class Period, indicating potential legal issues related to the company's disclosures and business performance [1][5]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Snowflake Class A common stock between June 27, 2023, and February 28, 2024 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by April 27, 2026, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Snowflake - The lawsuit claims that during the Class Period, Snowflake's defendants made positive statements about business performance while failing to disclose material negative impacts on consumption and revenues due to product efficiency gains and pricing strategies [5]. - The lawsuit alleges that the positive statements made by the defendants lacked a reasonable basis, leading to investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GSI Technology Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Allegations and Stock Impact - A post on Stockwits claimed that GSI Technology was concealing that their chip did not run the Gemma-3, only the pre-generation RAG phase, which is critical for AI workloads [3]. - Following this news, GSI Technology's stock price dropped by $1.08 per share, or 14.2%, closing at $6.52 per share on February 4, 2026 [3]. Group 2: Class Action Information - Investors who purchased GSI Technology securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

New York, New York--(Newsfile Corp. - February 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2026 [3]. - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth emerged [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of KDDI Corporation due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Allegations - The investigation is prompted by KDDI's announcement on February 6, 2026, regarding the postponement of its earnings report disclosure, citing uncertainties related to quarterly results and an internal investigation [3]. - Following this announcement, KDDI's American Depositary Receipts (ticker symbol "KDDIY") experienced a significant decline of 11.4% on the same day [4]. Group 2: Class Action and Investor Rights - Investors who purchased KDDI securities may be eligible for compensation through a class action lawsuit without incurring out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses and provides contact information for those interested in joining the action [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [5]. - In 2019, the firm secured over $438 million for investors, showcasing its capability and experience in handling such cases [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].

Core Points - Rosen Law Firm is reminding investors who purchased CoreWeave, Inc. securities between March 28, 2025, and December 15, 2025, of the lead plaintiff deadline on March 13, 2026 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has been filed against CoreWeave, and interested parties can join by contacting Rosen Law Firm [3][6] Case Details - The lawsuit alleges that CoreWeave's management made false and misleading statements regarding the company's ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [5] - It is claimed that these misstatements were likely to have a material negative impact on CoreWeave's revenue, leading to investor damages when the truth was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]